Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > Cancer Res Treat > Volume 41(1); 2009 > Article
Review Article Advances of Cancer Therapy by Nanotechnology
Xu Wang, Ph.D.1, Yiqing Wang, Ph.D.2, Zhuo Georgia Chen, Ph.D1, Dong M. Shin, M.D.1
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2009;41(1):1-11.
DOI: https://doi.org/10.4143/crt.2009.41.1.1
Published online: March 31, 2009

1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.

2Department of Biomedical Engineering, Emory University School of Medicine, Atlanta, GA, USA.

Correspondence: Dong M. Shin, M.D. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Rd. Building C. Room C3094. Atlanta, GA 30322, USA.
Tel: 1-404-778-2980, Fax: 1-404-778-5520, dmshin@emory.edu

Copyright © 2009 Korean Cancer Association

  • 20,478 Views
  • 191 Download
  • 131 Crossref
next
  • Recent developments in nanotechnology offer researchers opportunities to significantly transform cancer therapeutics. This technology has enabled the manipulation of the biological and physicochemical properties of nanomaterials to facilitate more efficient drug targeting and delivery. Clinical investigations suggest that therapeutic nanoparticles can enhance efficacy and reduced side effects compared with conventional cancer therapeutic drugs. Encouraged by rapid and promising progress in cancer nanotechnology, researchers continue to develop novel and efficacious nanoparticles for drug delivery. The use of therapeutic nanoparticles as unique drug delivery systems will be a significant addition to current cancer therapeutics.
Conventional chemotherapeutic drugs are distributed non-specifically in the body where they affect both cancerous and healthy cells, resulting in dose-related side effects and inadequate drug concentrations reaching the tumor. Non-specific drug delivery leads to significant complications that represent a serious obstacle to effective anticancer therapy. In addition, the occurrence of resistance phenomena reduces the efficacy of cancer treatment. To overcome the lack of specificity of conventional chemotherapeutic drugs, several ligand-targeted therapeutic strategies, including immunotoxins, radioimmunotherapeutics, and drug immunoconjugates, are being developed. Although these conjugated agents have shown promising efficacy compared with conventional chemotherapy drugs, limitations in their delivery efficiency still remain.
Recent progress in cancer nanotechnology raises exciting opportunities for specific drug delivery. Nanoparticles, particularly in the size range from 10 nm to 100 nm, are emerging as a class of therapeutics for cancer treatment. Nanoparticles can be composed of several functional molecules simultaneously, such as small molecule drugs, peptides, proteins, and nucleic acids. By using both passive and active targeting strategies, nanoparticles can increase the intracellular concentration of drugs in cancer cells while minimizing toxicity in normal cells; thereby enhancing anticancer effects and reducing systemic toxicity simultaneously, when compared with the therapeutic entities they contain. Furthermore, nanoparticles offer the potential to overcome drug resistance, since nanoparticles can bypass the P-glycoprotein efflux pump, one of the main drug resistance mechanisms, leading to greater intracellular accumulation.
The purpose of this review article is to summarize the results of the use of therapeutic nanoparticles in the clinic and discuss the opportunities and challenges faced by therapeutic nanoparticles. Thus, the first part will emphasize the key properties of therapeutic nanoparticles and how these properties affect the efficiency and specificity of nanoparticles as a drug delivery system. Next, we will summarize current clinical uses of the first-generation therapeutic nanoparticles and the advances in new generation of therapeutic nanoparticles currently under preclinical and clinical investigation. Finally, we will discuss how nanoparticles will be developed to improve their therapeutic efficacy and function for future cancer treatment.
Nanoparticles used for anticancer drug delivery can be made from a variety of materials, including polymers, dendrimers, liposomes, viruses, carbon nanotubes, and metals such as iron oxide and gold (Fig. 1). So far, almost all the nanoparticle delivery systems which have been approved by the FDA or are currently in clinic trials are based on polymers or liposomes (1).
1. Polymeric nanoparticles
Generally, polymers that are used for preparation of nanoparticles fall into two major categories: natural polymers and synthetic polymers. A number of natural polymers such as heparin, dextran, albumin, gelatine, alginate, collagen, and chitosan have been intensively investigated. Synthetic polymers including polyethylene glycol (PEG), polyglutamic acid (PGA), polylactic acid (PLA), polycarprolactone (PCL) and N-(2-hydroxypropyl)-methacrylamide copolymer (HPMA) have been exploited as well. General requirements for those polymers are biocompatibility, biodegradability, and their capacity to be functionalized (2).
The formation of polymeric nanoparticles has been summarized by several review articles (3,4). In most cases, the polymeric nanoparticle consists of two parts, a hydrophobic core which serves as the container for anticancer agents and a hydrophilic shell which stabilizes the nanoparticle in aqueous environments.
The drug can be loaded into polymeric nanoparticles through two methods: by physical entrapment or by chemical conjugation. A hydrophobic interaction between the core of the polymeric nanoparticle and the drug molecule allow the drug to be entrapped in the nanoparticle core. For instance, deoxychilic acid-modified heparin can self-assemble into 100~200 nm nanoparticles (5) and its hydrophobic core can be used to entrap 4~12% of the total weight of doxorubicin (6) When the drug molecule is covalently conjugated onto the polymer, the chemical properties of the linker between the drug and polymer are critical. If the linker is too stable, drug release may be delayed, while if the linker is too unstable, drug may be released before the nanoparticle reaches the tumor. Therefore, a proper linker is very important to the drug-polymer conjugate. A variety of pH-sensitive linkers have been developed such as hydrozone and cis-aconityl (7,8). These chemical bonds are stable in the blood circulation system (pH=7), but quickly decompose and release drug molecules inside the tumor where pH values typically drop below 5.5. Disulfide bonds are also very attractive because they can be cleaved by glutathione. The intracellular level of glutathione is much higher than its extracellular level, therefore, the disulfide linker is relatively stable while in blood circulation and becomes unstable and releases the drug molecules once it is internalized by cells (9,10).
It is important to note that dendrimers, synthetic superma cromolecules with highly branched repeated three dimensional structures, have emerged as important materials for biological application due to their unique features such as the precise control of size and shape, uncommon physical properties, controlled degradation, and the ability to place numerous functional groups on their periphery and/or core (11,12). There are more than 50 different types of dendrimers (13). Among them, polyamidoamine and poly (propylenemine) have been commercialized and used extensively as biomaterials in gene and drug delivery (14,15) and for nanoparticle encapsulation (16,17) in imaging (18,19).
2. Liposomal nanoparticles
Liposomes are self-assembling spherical particles with a membrane composed of phospholipid bilayers. The size of liposomes can range from 25 nm to 10 µm depending on the preparation method. They have been studied as candidates for drug delivery for the last 50 years since being first discovered by Bangham (20). The synthesis of liposomal nanoparticles has been reviewed by Bellare, et al (21). Drug delivery systems based on unmodified liposomes are limited by their short blood circulation time. This is mainly due to the fast clearance of liposomes by macrophages of the reticuloendothelial system (RES) (22). The second generation of polymer-coated liposomes can dramatically increase blood circulation times from several minutes up to 3 days.
3. Gold and iron oxide nanoparticles
Recently, several novel nanotechnology concepts have been applied to the development of a new generation of anti-cancer drug delivery systems. Gold nanoparticles can be synthesized through the reduction of HAlCl4 with a very narrow polydispersity. Several gold nanoparticle anticancer drug delivery systems have been reported and showed good in vitro results (23).Although it seems that gold is inert under physiological environments, the long term toxicity of gold nanoparticles remains an unanswered question. One attractive property of gold nanoparticles is that gold concentrations are naturally low in animal bodies, allowing the convenient use of this nanoparticle model for in vivo pharmacokinetic and biodistribution studies (24).
It is worth mentioning that a gold nanorod formulation is showing very promising potential as a photothermal therapy agent. Gold nanorod can generate heat when it is radiated by a near infra-red (IR) laser (wavelengt > 650 nm). At this range, the laser is relatively safe to the tissue and organs. Once the gold nanorod has accumulated inside the tumor through passive/active targeting, it can be heated locally up to 43℃ (25) by radiation with a near IR laser to destroy the tumor without causing damage to surrounding healthy tissues (27).
Iron oxide nanoparticles have been clinically used as imaging agents for MRI. Recently a number of research groups have investigated them as drug carriers while retaining their imaging functions (26-28). One unique advantage of iron oxide nanoparticle delivery systems is that they can be delivered in a targeted manner to a desired region by applying an external magnetic field.
A suitable nanoparticle size is very important for efficient drug delivery. Generally, 10~100 nm is considered the optimal size for nanoparticle drug carriers. If the particle size is less than 10 nm, the nanoparticles will be quickly eliminated by renal clearance (threshhold < 6 nm). At sizes greater than 100 nm, the chance of the particle being captured by the RES will dramatically increase (29).
A proper surface coating is essential to the stability and circulation time of nanoparticle delivery systems. For instance, a sodium citrate-stabilized gold particle aggregates in PBS within several minutes. But once coated with thiol-terminated polyethylene glycol (PEG) polymer, this nanoparticle is stable not only in PBS but also under low or high pH conditions (32). Generally, a neutral-charged nanoparticle can achieve a long circulation time and reduce the chance of nanoparticle capture by the immune system.
1. Passive targeting
Table 1 lists nanoparticles that have been used in the clinic and utilize passive targeting to achieve their selective delivery to tumors. Passive targeting takes advantage of the inherent size of nanoparticles and the unique properties of tumor vasculature (30-33). As tumors grow and begin to outstrip the available supply of oxygen and nutrients, they release cytokines and other signaling molecules that recruit new blood vessels to the tumor in a process called angiogenesis. Unlike the tight blood vessels in normal tissues, angiogenic blood vessels in tumor tissues have gaps as large as 600 to 800 nm between adjacent endothelial cells (34,35). This defective vascular architecture coupled with poor lymphatic drainage induces an enhanced permeability and retention effect (EPR) (36,37), Through these gaps, nanoparticles can selectively accumulate into the tumor interstitium (38) (Fig. 2).
In general, the accumulation of nanoparticles in tumor tissues is dependent on several factors including the size, surface characteristics, and circulation half-life of the nanoparticles and the degree of angiogenesis of the tumor (39). It is speculated that nanoparticles with a size between 10 and 100 nm will be optimal for tumor accumulation. For example, smaller polymeric micelles (20 nm) have been shown to accumulate more readily in tumors than larger liposomes (100 nm) (40,41). Proper surface characteristics and longer circulation times of nanoparticles can also improve tumor uptake, as described earlier. The unmodified phospholipid surface of liposomes can attract plasma proteins and thus recognition by the mononuclear phagocytic system (MPS), resulting in their rapid clearance from the circulation. This property impedes the distribution of liposome-associated drugs to solid tumors. Surface-modified (stealth) liposomes have solved the problem of fast clearance from the circulation, yielding liposomes with a significantly increased half-life in the blood (42,43). Dramatically reduced clearance rates have also been obtained with other nanoparticles such as Abraxane (44), Xyotax (45) and IT-101 (46). Tumor vascularization also affects nanoparticle accumulation; usually nanoparticles accumulate poorly in poorly vascularized tumors, small pre-angiogenic tumors, or large necrotic tumors.
As drug delivery systems, nanoparticles have shown an ability to improve pharmacokinetics, pharmacodynamics, efficacy, and to reduce the toxicity of associated drugs (40). For example, Abraxane (ABI-007), an albumin-bound nanoparticle of paclitaxel (Taxol) which has been approved for the treatment of metastatic breast cancer, showed significant greater efficacy than free paclitaxel in a phase III clinic trial (47). Despite the increased dose of paclitaxel in the Abraxane group, the incidence of grade 4 neutropaenia was significantly lower than in patients treated with free paclitaxel. Pharmacokinetic studies also showed that paclitaxel clearance and the volume of distribution were higher for Abraxane than for paclitaxel: Clearance was 13 litres per hour per m2 for Abraxane versus 14.76 litres per hour per m2 for paclitaxel (p=0.048), and distribution was 663.8 litres per m2 for Abraxane versus 433.4 litres per m2 for paclitaxel (p=0.04) (44). Similar to Abraxane, NK105, a micellar nanoparticle formulation of paclitaxel also showed improved pharmacokinetics, pharmacodynamics, efficacy, and reduced toxicity as compared with free paclitaxel in a preclinical study and a phase I trial (48,49). The plasma area under the curve (AUC) value was approximately 90-fold greater for NK105 than for free paclitaxel and the tumor AUC value was 25-fold higher for NK105 than for free paclitaxel in an animal model (48). In patients, the plasma AUC of NK105 at 180 mg/m2 was approximately 30-fold greater than that of the conventional formulation of paclitaxel (49). NK105 showed significantly more potent antitumor activity in a human colorectal cancer cell line HT-29 xenograft than free paclitaxel, due to enhanced accumulation of the drug in the tumor (48). The phase I trial showed that NK105 was well tolerated and effective in patients with pancreatic cancer (50). These differences in pharmacokinetic properties may contribute to the increased drug accumulation inside the tumor observed with nanoparticles compared with the corresponding free drugs. Other nanoparticles currently used in the clinic or undergoing clinic trials also showed an improved pharmacokinetic profile compared with the respective free drugs, such as Doxil, a PEG-liposome loaded with doxorubicin (DOX) (51), SP1049C, a pluronic micelle loaded with DOX (40), NK911, a PEG-Asp micelle loaded with DOX (52), and Xyotax, a polyglutamic acid nanoparticle carrying paclitaxel (45).
2. Active targeting
The nanoparticles listed in Table 1 that have been used in the clinic so far mostly utilize the EPR effect of tumors and the tumor microenvironment to promote their selective delivery to tumors. However, certain limitations of non-targeted nanoparticles as a drug delivery system still remain. For example, in the case of the EPR effect, although poor lymphatic drainage helps the extravasated drugs to be enriched in the tumor interstitium, it also induces drug outflow from the cells as a result of higher osmotic pressure in the interstitium, which eventually leads to drug redistribution in some portions of the cancer tissue (53). Most importantly, accumulation merely within the tumor microenvironment by the EPR effect may not always correlate with therapeutic efficacy since internalization into the tumor cells is required for most anticancer drugs to exert their biological functions. To overcome these limitations, a rational approach is to incorporate a targeting moiety on the nanoparticle surface. The targeting moiety is expected to bind a tumor-associated antigen or receptor and facilitate the delivery of nanoparticles to the intracellular site of drug action, enabling a greater therapeutic effect (Fig. 3). Recent preclinical studies have shown that targeted nanoparticles have better antitumor activity compared with non-targeted nanoparticles (54-57). Although targeted nanoparticles may not always mediate an increase in tumor drug accumulation when compared with non-targeted nanoparticles, targeted nanoparticles show greater intracellular drug delivery to cancer cells than non-targeted nanoparticles, resulting in dramatically increased antitumor efficacy (54-56). These findings suggest that the primary role of the targeting ligands is to enhance cellular uptake into cancer cells and to minimize cellular uptake in normal cells.
Although current studies have shown that the use of targeted nanoparticles as a drug delivery system is a promising strategy to treat human cancers, it is still in its early stage of development. Clinical data using targeted nanoparticles are limited since most targeted nanoparticles have not yet reached the clinic. Only a few targeted nanoparticles are currently under clinical investigation. One is MCC-465, which is an immunoliposome-encapsulated doxorubicin (Dox). The liposome is tagged with PEG and the F(ab')2 fragment of the human monoclonal antibody GAH, which recognizes a cell surface molecule on various types of cancer cells (58).Phase I studies have indicated that the PK parameters of MCC-465 differ from those of free Dox, but were very similar to those of Doxil (non-targeted liposome-encapsulated Dox) in humans. In terms of skin toxicity, the patients who received MCC-465 did not experience any severe skin toxicity such as palmar-plantar erythrodysesthesia (PPE) or mucositis, unlike the patients who received Doxil (58). Besides MCC-465, other examples of targeted therapeutic nanoparticles include MBP-426 which contains the cytotoxic platinum-based drug oxaliplatin in a liposome (59), SGT-53, a liposome containing a plasmid coding for the tumor suppressor p53 (60), and CALAA-01, a polymer-siRNA conjugate (61,62) (Table 2) . These nanoparticles all target the transferrin receptor which is upregulated in many types of cancer (63).
3. Selection of target receptor and ligand
Selection of the target receptor or antigen on cancer cells is crucial for the optimal design of targeted nanoparticles. In general, cell-surface antigens and receptors should have several properties that render them particularly suitable as tumor-specific targets. First, they should be abundantly and uniquely expressed on tumor cells, but negligibly or less expressed on normal cells. Second, they should have a high density on tumor cells.
A targeting ligand should selectively and successfully transport nanoparticles into targeted cancer cells. It is believed that internalization of nanoparticles after binding to targeted tumor cells is necessary for good therapeutic responses, so whether the targeted nanoparticles can be internalized is an important issue in the selection of proper targeting ligand. Use of a ligand that can not trigger the internalization process may result in drug release outside the cell and its redistribution to the surrounding normal tissues.
A variety of targeting ligands, including antibodies, antibody fragments, peptides, growth factors, and aptamers (64), have been used to facilitate the uptake of carriers into target cells (65-76).
Drug resistance remains one of the major challenges in cancer therapy. A number of mechanisms for drug resistance have been described. Drug resistance can be caused by physiological barriers (non-cellular based mechanisms), or alterations in the biology and biochemistry of cancer cells (cellular mechanisms). Non-cellular drug resistance can be caused by poorly vascularized tumor regions and/or physiological barriers that greatly reduce drug access to the tumor tissues, thus protecting cancerous cells from drug-induced cytotoxicity. Cellular drug resistance can be due to overexpressed drug export pumps, such as P-glycoprotein (p-gp) and other drug-resistance proteins, increased DNA repair capacity, and reduced apoptosis regulation.
Among these mechanisms, the roles of the drug efflux pumps are the most extensively investigated. P-glycoprotein (p-gp), a product of the MDR1 gene, is a 170-kD transmembrane glycoprotein that functions as an efflux pump to remove drug from cells. Several specific p-gp inhibitors have been investigated to overcome drug resistance. Although in preclinical studies, some of these p-gp inhibitors have shown the restoration of cancer cell sensitivity to anticancer drugs, the clinical trials results have been disappointing (77,78).
Alternative strategies for overcoming drug resistance have been studied. Newly developed drug delivery systems, including nanoparticle, allow selective drug accumulation in tumor tissues, tumor cells, or even compartments of tumor cells. Because with the aid of a targeting moiety nanoparticles enter cells through endocytosis, it is expected that they can bypass the p-gp efflux pump, leading to their greater intracellular accumulation (Fig. 3). Many nanoparticles have been used to overcome or minimize drug resistance in preclinical studies and the results are very promising. For example, doxorubicin (DOX)-loaded poly (alkyl cyanoacrylate) nanoparticles (79), PACA nanoparticle (80,81), and IT-101 (a nanoparticulate conjugate of 20 (S)-camptothecin) (82) have shown the ability to overcome drug resistance in the tested models. And most importantly, the ability of targeted nanoparticles to overcome drug resistance has been confirmed in humans. It has been demonstrated in clinical studies that liposomal doxorubicin is able to overcome drug resistance in AIDS-related Kaposi's sarcoma (83,84). Also, clinical trials showed positive results using nanoparticles in patients who had previously failed chemotherapy (83,85,86). Ligand-targeted strategies, especially those using receptor-targeting ligands, have also been applied to overcome drug resistance since these ligands are internalized via receptor-mediated endocytosis, bypassing the plasma membrane where p-gp primarily acts. As an example, folate receptor-targeted pH-sensitive polymeric micelles containing DOX (87) and transferrin-conjugated paclitaxel nanoparticles exhibited greater cytotoxicity than the respective free drugs in a drug-resistant model (88). As illustrated, using nanoparticles as a drug delivery system may be able to overcome certain kinds of cancer drug resistance.
An important consideration in nanoparticle development is the biological behavior of carrier constituents and their potential toxicity, especially during chronic administration. Many candidate polymers have been defined with particular toxicities, such as hematotoxicity, complementactivation, carcinogenicity, teratogenicity, and immunogenicity (89,90), indicating the importance of choosing safe polymers for the design of nanoparticles. In addition, the biological properties of polymers are molecular weight-dependent and can be changed once the respective conjugates are prepared. Therefore, careful characterization of the potential toxicity of both the polymer and the final nanoparticle is critically important. For non-biodegradable polymers, potential toxicity is concerning when the polymer molecular weight is greater than the renal threshold. Increased understanding of the potentially deleterious properties of polymers leads to the design of new and safer polymeric nanoparticles.
Currently, most nanoparticles use nontoxic and biodegradable ingredients, so toxicities associated with the carrier molecules per se tend to be mild. However, particular nanoparticles cause increased accumulation of drugs in MPS cells in the liver, spleen, and bone marrow, with the possibility of increased toxicities to these organs. Among these organs, the liver has been identified in many studies as the primary organ responsible for reticuloendothelial capture of nanoparticles, often due to phagocytosis by Kupffer cells (91,92). Hepatic uptake has been shown to be a main mechanism of hepatic clearance from the blood circulation following the intravenous injection of nanoparticles. In addition to hepatic accumulation, some nanoparticles have been reported to cause liver injury (decreased function and hepatic morphology changes) (93,94). For example, intravenous administration of cationic PAMAM dendrimers caused liver injury when administered intravenously to mice (95). Hepatotoxicity has also been observed in mice treated orally with nano-zinc particles (96). Also there are safety concerns with particular nanoparticles that are able to cross the blood brain barrier. Lessons have been learned from many of the early clinical studies. For example, due to neurotoxicity, a clinical trial testing an HPMA-conjugated paclitaxel was terminated (97). The failure of MAG-camptothecin due to cumulative bladder toxicity in phase I was also reported (98).
Attempts are being made to decrease the uptake of nanoparticles by MPS cells and to increase their accumulation in the active site, through polymer or nanoparticle surface modifications, and/or incorporating targeting ligands (54,99,100). With more rational design, many nanoparticles have shown an improved safety profile and enhanced antitumor efficacy compared with free drugs in preclinical and clinical studies (100-104). For example, Doxil (PEG-liposome loaded with doxorubicin) showed a reduction in cardiotoxicity over that of doxorubicin in a clinical study (103,104). Abraxane (albumin nanoparticle loaded with paclitaxel) showed a greater therapeutic outcome compared with free paclitaxel and, taking advantage of the water solubility of the nanoparticle, successfully eliminated the side effects associated with the toxic vehicle Cremophor EL (47).
Nanoparticles provide opportunities for designing and tuning properties that are not possible with other types of therapeutic drugs, and have shown a bright future as a new generation of cancer therapeutics. Furthermore, the development of multifunctional nanoparticles may eventually render nanoparticles able to detect and kill cancer cells simultaneously. Although there are certain critical questions and many challenges remaining for the clinical development of nanoparticles, as more clinical data are available, further understanding in nanotechnology will certainly lead to the more rational design of optimized nanoparticles with improved selectivity, efficacy, and safety.
Acknowledgements
We thank Dr. Anthea Hammond for her critical reading of the manuscript.

This work was supported by National Cancer Institute (NCI) Specialized Program of Research Excellence (SPORE) grant (P50CA128613) to D.M. Shin and Centers of Cancer Nanotechnology Excellence (CCNE) grant (U54 CA119338) to D.M. Shin and Z.G. Chen.

  • 1. Qiu LY, Bae YH. Polymer architecture and drug delivery. Pharm Res. 2006;23:1–30. PMID: 16392022ArticlePubMed
  • 2. Tong R, Cheng JJ. Anticancer polymeric nanomedicines. Polym Rev. 2007;47:345–381. Article
  • 3. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310–1316. PMID: 18316549ArticlePubMed
  • 4. Zhang GZ, Niu AZ, Peng SF, Jiang M, Tu YF, Li M, et al. Formation of novel polymeric nanoparticles. Acc Chem Res. 2001;34:249–256. PMID: 11263883ArticlePubMed
  • 5. Park K, Kim K, Kwon IC, Kim SK, Lee S, Lee DY, et al. Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir. 2004;20:11726–11731. PMID: 15595804ArticlePubMed
  • 6. Park K, Lee GY, Kim YS, Yu M, Park RW, Kim IS, et al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release. 2006;114:300–306. PMID: 16884806ArticlePubMed
  • 7. Kratz F, Beyer U, Schutte MT. Drug-polymer conjugates containing acid-cleavable bonds. Crit Rev Ther Drug Carrier Syst. 1999;16:245–288. PMID: 10706520ArticlePubMed
  • 8. Ulbrich K, Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev. 2004;56:1023–1050. PMID: 15066758ArticlePubMed
  • 9. Jones DP, Carlson JL, Samiec PS, Sternberg P, Mody VC, Reed RL, et al. Glutathione measurement in human plasma Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin Chim Acta. 1998;275:175–184. PMID: 9721075ArticlePubMed
  • 10. Koo AN, Lee HJ, Kim SE, Chang JH, Park C, Kim C, et al. Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery. Chem Commun (Camb). 2008;6570–6572. PMID: 19057782ArticlePubMed
  • 11. Bosman AW, Janssen HM, Meijer EW. About dendrimers: Structure, physical properties, and applications. Chem Rev. 1999;99:1665–1688. PMID: 11849007ArticlePubMed
  • 12. Fischer M, Vogtle F. Dendrimers: From design to application - A progress report. Angew Chem Int Ed Engl. 1999;38:885–905. Article
  • 13. Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochimica Polonica. 2001;48:199–208. PMID: 11440170ArticlePubMed
  • 14. Dykes GM. Dendrimers: a review of their appeal and applications. J Chem Tech Biot. 2001;76:903–918. Article
  • 15. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today. 2001;6:427–436. PMID: 11301287ArticlePubMed
  • 16. Balogh L, Tomalia DA. Poly(amidoamine) dendrimer-templated nanocomposites. 1. Synthesis of zerovalent copper nanoclusters. J Am Chem Soc. 1998;120:7355–7356. Article
  • 17. Crooks RM, Zhao MQ, Sun L, Chechik V, Yeung LK. Dendrimer-encapsulated metal nanoparticles: Synthesis, characterization, and applications to catalysis. Acc Chem Res. 2001;34:181–190. PMID: 11263876ArticlePubMed
  • 18. Balogh L, Bielinska A, Eichman JD, Valluzzi R, Lee I, Baker JR, et al. Dendrimer nanocomposites in medicine. Chim Oggi. 2002;20:35–40.
  • 19. Zheng J, Dickson RM. Individual water-soluble dendrimer-encapsulated silver nanodot fluorescence. J Am Chem Soc. 2002;124:13982–13983. PMID: 12440882ArticlePubMed
  • 20. Bangham AD, Horne RW. Negative Staining of Phospholipids + Their Structural Modification by-Surface Active Agents as Observed in Electron Microscope. J Mol Biol. 1964;8:660–668. PMID: 14187392ArticlePubMed
  • 21. Watwe RM, Bellare JR. Manufacture of Liposomes - a Review. Curr Sci. 1995;68:715–724.
  • 22. Gabizon AA. Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet. Clin Cancer Res. 2001;7:223–225. PMID: 11234871PubMed
  • 23. Cheng Y, Samia AC, Meyers JD, Panagopoulos I, Fei BW, Burda C. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc. 2008;130:10643–10647. PMID: 18642918ArticlePubMedPMC
  • 24. Qian X, Peng XH, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol. 2008;26:83–90. PMID: 18157119ArticlePubMed
  • 25. Dewey WC. Arrhenius Relationships from the Molecule and Cell to the Clinic. Int J Hyperthermia. 1994;10:457–483. PMID: 7963805ArticlePubMed
  • 26. Sun C, Lee JSH, Zhang MQ. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60:1252–1265. PMID: 18558452ArticlePubMedPMC
  • 27. Jun YW, Lee JH, Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed Engl. 2008;47:5122–5135. PMID: 18574805ArticlePubMed
  • 28. Xu CJ, Sun SH. Monodisperse magnetic nanoparticles for biomedical applications. Polym Int. 2007;56:821–826. Article
  • 29. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7:771–782. PMID: 18758474ArticlePubMed
  • 30. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969–976. PMID: 15258594ArticlePubMed
  • 31. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005;2:194–205. PMID: 15934780ArticlePubMed
  • 32. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–4646. PMID: 16892078ArticlePubMed
  • 33. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25:9–34. PMID: 16680569ArticlePubMed
  • 34. Edens HA, Levi BP, Jaye DL, Walsh S, Reaves TA, Turner JR, et al. Neutrophil transepithelial migration: evidence for sequential, contact-dependent signaling events and enhanced paracellular permeability independent of transjunctional migration. J Immunol. 2002;169:476–486. PMID: 12077279ArticlePubMed
  • 35. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58:97–110. PMID: 18227410ArticlePubMed
  • 36. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6:559–593. PMID: 3327633ArticlePubMed
  • 37. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649–1659. PMID: 15350294ArticlePubMed
  • 38. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006;107:459–466. PMID: 16795065ArticlePubMed
  • 39. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–1822. PMID: 15031496ArticlePubMed
  • 40. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007;24:1029–1046. PMID: 17385025ArticlePubMed
  • 41. Weissig V, Whiteman KR, Torchilin VP. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm Res. 1998;15:1552–1556. PMID: 9794497ArticlePubMed
  • 42. Papahadjopoulos D, Gabizon A. Liposomes designed to avoid the reticuloendothelial system. Prog Clin Biol Res. 1990;343:85–93. PMID: 2198586PubMed
  • 43. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24:1211–1217. PMID: 17033654ArticlePubMed
  • 44. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11:4136–4143. PMID: 15930349ArticlePubMed
  • 45. Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res. 2005;11:7834–7840. PMID: 16278406ArticlePubMed
  • 46. Schluep T, Cheng J, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol. 2006;57:654–662. PMID: 16133526ArticlePubMed
  • 47. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803. PMID: 16172456ArticlePubMed
  • 48. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer. 2005;92:1240–1246. PMID: 15785749ArticlePubMedPMC
  • 49. Kato K, Hamaguchi T, Yasui H, Okusaka T, Ueno H, Ikeda M, et al. Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle in patients with advanced cancer. Proc Am Soc Clin Oncol. 2006;24:83S(abstract 2018)Article
  • 50. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer. 2007;97:170–176. PMID: 17595665ArticlePubMedPMC
  • 51. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta. 2004;1663:167–177. PMID: 15157619ArticlePubMed
  • 52. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004;91:1775–1781. PMID: 15477860ArticlePubMedPMC
  • 53. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000;60:4251–4255. PMID: 10945638PubMed
  • 54. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732–6740. PMID: 16818648ArticlePubMed
  • 55. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007;104:15549–15554. PMID: 17875985ArticlePubMedPMC
  • 56. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103:6315–6320. PMID: 16606824ArticlePubMedPMC
  • 57. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008;105:2586–2591. PMID: 18272481ArticlePubMedPMC
  • 58. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol. 2004;15:517–525. PMID: 14998859ArticlePubMed
  • 59. MedBiopharm Co. L.Safety study of MBP-426 (liposomal oxaliplatin suspension for injection) to treat advanced or metastatic solid tumors. ClinivalTrials.gov web site 2008 [online]. http;//www.clinicaltrials.gov/ct/show/NCT00355888/
  • 60. SynerGene Therapeutics Isafety study of infusion of SGT-53 tp treat solid tumors. ClinicalTrials.gov web site 2008 [online]. http://www.clincaltrials.gov/ct2/show/NCT00470613/
  • 61. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A. 2007;104:5715–5721. PMID: 17379663ArticlePubMedPMC
  • 62. Calando-PharmaceuticalsSafety study of CALAA-01 to treat solid tumor cancers. ClinicalTrials.gov web site 2008 [online]. http://www.clincaltrials.gov/ct/show/NCT00689065
  • 63. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol. 1983;36:539–545. PMID: 6302135ArticlePubMedPMC
  • 64. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105:17356–17361. PMID: 18978032ArticlePubMedPMC
  • 65. Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 2003;63:4062–4066. PMID: 12874007PubMed
  • 66. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000;60:6950–6957. PMID: 11156395PubMed
  • 67. Guillemard V, Uri Saragovi H. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene. 2004;23:3613–3621. PMID: 15034547ArticlePubMed
  • 68. Guillemard V, Saragovi HU. Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets. 2004;4:313–326. PMID: 15180497ArticlePubMed
  • 69. Pechar M, Ulbrich K, Subr V, Seymour LW, Schacht EH. Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin. Bioconjug Chem. 2000;11:131–139. PMID: 10725088ArticlePubMed
  • 70. Lu ZR, Gao SQ, Kopeckova P, Kopecek J. Modification of cyclosporin A and conjugation of its derivative to HPMA copolymers. Bioconjug Chem. 2001;12:129–133. PMID: 11170375ArticlePubMed
  • 71. Li C. Poly(L-glutamic acid)--anticancer drug conjugates. Adv Drug Deliv Rev. 2002;54:695–713. PMID: 12204599ArticlePubMed
  • 72. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147–162. PMID: 10699311ArticlePubMed
  • 73. Ni S, Stephenson SM, Lee RJ. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res. 2002;22:2131–2135. PMID: 12174894PubMed
  • 74. Backer MV, Gaynutdinov TI, Aloise R, Przekop K, Backer JM. Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery. Protein Expr Purif. 2002;26:455–461. PMID: 12460770ArticlePubMed
  • 75. Backer MV, Aloise R, Przekop K, Stoletov K, Backer JM. Molecular vehicles for targeted drug delivery. Bioconjug Chem. 2002;13:462–467. PMID: 12009934ArticlePubMed
  • 76. Saba NF, Wang X, Müller S, Tighiouart M, Cho K, Nie S, Chen Z(G), Shin DM. Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug. Head and Neck. 2008;in pressArticlePubMedPMC
  • 77. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer. 1996;32A:1070–1081. PMID: 8763349Article
  • 78. McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther. 2007;113:429–441. PMID: 17208306ArticlePubMed
  • 79. Pepin X, Attali L, Domrault C, Gallet S, Metreau JM, Reault Y, et al. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J Chromatogr B Biomed Sci Appl. 1997;702:181–191. PMID: 9449570ArticlePubMed
  • 80. Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release. 2003;93:151–160. PMID: 14636721ArticlePubMed
  • 81. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release. 1999;60:121–128. PMID: 10370176ArticlePubMed
  • 82. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006;12:1606–1614. PMID: 16533788ArticlePubMed
  • 83. Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol. 1997;15:653–659. PMID: 9053490ArticlePubMed
  • 84. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat. 2003;6:271–279. PMID: 14643297ArticlePubMed
  • 85. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;108:241–250. PMID: 17476588ArticlePubMed
  • 86. Nemunaitis J, Cunningham C, Senzer N, Gray M, Oldham F, Pippen J, et al. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest. 2005;23:671–676. PMID: 16377585ArticlePubMed
  • 87. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release. 2005;103:405–418. PMID: 15763623ArticlePubMed
  • 88. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005;2:373–383. PMID: 16196490ArticlePubMed
  • 89. Rihova B, Riha I. Immunological problems of polymer-bound drugs. Crit Rev Ther Drug Carrier Syst. 1985;1:311–374. PMID: 2420476PubMed
  • 90. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2:347–360. PMID: 12750738ArticlePubMed
  • 91. Cagle DW, Kennel SJ, Mirzadeh S, Alford JM, Wilson LJ. In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc Natl Acad Sci U S A. 1999;96:5182–5187. PMID: 10220440ArticlePubMedPMC
  • 92. Ogawara K, Furumoto K, Takakura Y, Hashida M, Higaki K, Kimura T. Surface hydrophobicity of particles is not necessarily the most important determinant in their in vivo disposition after intravenous administration in rats. J Control Release. 2001;77:191–198. PMID: 11733087ArticlePubMed
  • 93. Fernandez-Urrusuno R, Fattal E, Porquet D, Feger J, Couvreur P. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol Appl Pharmacol. 1995;130:272–279. PMID: 7871540ArticlePubMed
  • 94. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res. 1996;30:53–65. PMID: 8788106ArticlePubMed
  • 95. Neerman MF, Zhang W, Parrish AR, Simanek EE. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery. Int J Pharm. 2004;281:129–132. PMID: 15288350ArticlePubMed
  • 96. Wang B, Feng WY, Wang TC, Jia G, Wang M, Shi JW, et al. Acute toxicity of nano- and micro-scale zinc powder in healthy adult mice. Toxicol Lett. 2006;161:115–123. PMID: 16165331ArticlePubMed
  • 97. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs. 2001;12:315–323. PMID: 11335787ArticlePubMed
  • 98. Wachters FM, Groen HJ, Maring JG, Gietema JA, Porro M, Dumez H, et al. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br J Cancer. 2004;90:2261–2267. PMID: 15150611ArticlePubMedPMC
  • 99. Clift MJ, Rothen-Rutishauser B, Brown DM, Duffin R, Donaldson K, Proudfoot L, et al. The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol Appl Pharmacol. 2008;232:418–427. PMID: 18708083ArticlePubMed
  • 100. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65:5317–5324. PMID: 15958579ArticlePubMed
  • 101. Benny O, Fainaru O, Adini A, Cassiola F, Bazinet L, Adini I, et al. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol. 2008;26:799–807. PMID: 18587385ArticlePubMedPMC
  • 102. Langer CJ. CT-2103: emerging utility and therapy for solid tumours. Expert Opin Investig Drugs. 2004;13:1501–1508. ArticlePubMed
  • 103. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine. 2007;2:567–583. PMID: 18203425PubMedPMC
  • 104. Batist G. Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol. 2007;7:72–74. PMID: 17652807ArticlePubMed
  • 105. Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma. 2005;46:795–802. PMID: 16019523ArticlePubMed
  • 106. Allison SD. Liposomal drug delivery. J Infus Nurs. 2007;30:89–95. PMID: 17413493ArticlePubMed
  • 107. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005;2:369–381. PMID: 16305440ArticlePubMed
  • 108. White SC, Lorigan P, Margison GP, Margison JM, Martin F, Thatcher N, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer. 2006;95:822–828. PMID: 16969346ArticlePubMedPMC
  • 109. Rosenthal DI, Yom SS, Liu L, Machtay M, Algazy K, Weber RS, et al. A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs. 2002;20:343–349. PMID: 12201498ArticlePubMed
  • 110. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol. 2001;12:493–496. PMID: 11398881ArticlePubMed
  • 111. Neville ME, Boni LT, Pflug LE, Popescu MC, Robb RJ. Biopharmaceutics of liposomal interleukin 2, oncolipin. Cytokine. 2000;12:1691–1701. PMID: 11052821ArticlePubMed
  • 112. Ciuleanu T, Diculescu M, Hoepffner NM, Trojan J, Sailer V, Zalupski M, et al. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers. Invest New Drugs. 2007;25:385–390. PMID: 17364234ArticlePubMed
  • 113. Clamp AR, Schoffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, et al. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008;61:579–585. PMID: 17520255ArticlePubMed
  • 114. Guo W, Johnson JL, Khan S, Ahmad A, Ahmad I. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. Anal Biochem. 2005;336:213–220. PMID: 15620886ArticlePubMed
  • 115. Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol. 2004;93:229–232. PMID: 15047241ArticlePubMed
  • 116. Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol. 2006;58:759–764. PMID: 16847673ArticlePubMed
  • 117. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007;18:2009–2014. PMID: 17785767ArticlePubMed
  • 118. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, Kim KY, et al. Systemic and Specific Delivery of Small Interfering RNAs to the Liver Mediated by Apolipoprotein A-I. Mol Ther. 2007;1145–1152. PMID: 17440441ArticlePubMed
  • 119. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10:3708–3716. PMID: 15173077ArticlePubMed
  • 120. Matsumura Y. [Micelle carrier system in clinical trial]. Nippon Rinsho. 2006;64:316–321. PMID: 16454187
  • 121. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer. 2004;90:2085–2091. PMID: 15150584ArticlePubMedPMC
  • 122. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005;93:678–687. PMID: 16222314ArticlePubMedPMC
  • 123. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006;66:10048–10056. PMID: 17047068ArticlePubMed
  • 124. Negishi T, Koizumi F, Uchino H, Kuroda J, Kawaguchi T, Naito S, et al. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br J Cancer. 2006;95:601–606. PMID: 16909136ArticlePubMedPMC
  • 125. Albain KS, Belani CP, Bonomi P, O'Byrne KJ, Schiller JH, Socinski M. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer. 2006;7:417–419. PMID: 16800969ArticlePubMed
  • 126. Bilim V. Technology evaluation: PK1, Pfizer/Cancer Research UK. Curr Opin Mol Ther. 2003;5:326–330. PMID: 12870445PubMed
  • 127. Thomson AH, Vasey PA, Murray LS, Cassidy J, Fraier D, Frigerio E, et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br J Cancer. 1999;81:99–107. PMID: 10487619ArticlePubMedPMC
  • 128. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002;20:1668–1676. PMID: 11896118ArticlePubMed
  • 129. Bissett D, Cassidy J, de Bono JS, Muirhead F, Main M, Robson L, et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br J Cancer. 2004;91:50–55. PMID: 15187995ArticlePubMedPMC
  • 130. Sarapa N, Britto MR, Speed W, Jannuzzo M, Breda M, James CA, et al. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol. 2003;52:424–430. PMID: 12904897ArticlePubMed
  • 131. Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res. 2004;10:3386–3395. PMID: 15161693ArticlePubMed
  • 132. Campone M, Rademaker-Lakhai JM, Bennouna J, Howell SB, Nowotnik DP, Beijnen JH, et al. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol. 2007;60:523–533. PMID: 17308894ArticlePubMed
  • 133. Danhauser-Riedl S, Hausmann E, Schick HD, Bender R, Dietzfelbinger H, Rastetter J, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs. 1993;11:187–195. PMID: 7505268ArticlePubMed
  • 134. Shiose Y, Kuga H, Yamashita F, Hashida M. Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f. J Pharm Biomed Anal. 2007;43:1290–1296. PMID: 17127025ArticlePubMed
  • 135. Soepenberg O, de Jonge MJ, Sparreboom A, de Bruin P, Eskens FA, de Heus G, et al. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res. 2005;11:703–711. PMID: 15701859ArticlePubMed
  • 136. Ochi Y, Shiose Y, Kuga H, Kumazawa E. A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951. Cancer Chemother Pharmacol. 2005;55:323–332. PMID: 15517271ArticlePubMed
  • 137. Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev. 2003;55:217–250. PMID: 12564978ArticlePubMed
  • 138. Rowinsky EK, Rizzo J, Ochoa L, Takimoto CH, Forouzesh B, Schwartz G, et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol. 2003;21:148–157. PMID: 12506184ArticlePubMed
  • 139. Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008;14:1888–1896. PMID: 18347192ArticlePubMed
  • 140. NektarTherapeuticsStudy to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Breast Cancer. Clinical Trials.gov web site 2008 [online]. http://clinicaltrials.gov/ct2/show/NCT00802945
  • 141. Gradishar WJ. Albumin-bound nanoparticle paclitaxel. Clin Adv Hematol Oncol. 2005;3:348–349. PMID: 16167008PubMed
  • 142. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041–1053. PMID: 16722814ArticlePubMed
  • 143. Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release. 2004;100:247–256. PMID: 15544872ArticlePubMed
  • 144. Nasongkla N, Shuai X, Ai H, Weinberg BD, Pink J, Boothman DA, et al. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed Engl. 2004;43:6323–6327. PMID: 15558662ArticlePubMed
  • 145. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A. 2003;100:6039–6044. PMID: 12716967ArticlePubMedPMC
  • 146. Jeong YI, Seo SJ, Park IK, Lee HC, Kang IC, Akaike T, et al. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int J Pharm. 2005;296:151–161. PMID: 15885467ArticlePubMed
Fig. 1
Illustration of (A) polymer based nanoparticles; (B). Liposome based nanoparticles; and (C). Iron oxide or gold nanoparticles.
crt-41-1-g001.jpg
Fig. 2
Schematic diagram of nanoparticle accumulation in tumor tissue through EPR effect. Normal tissue vasculatures are lined by tight endothelial cells, thereby preventing nanoparticle drugs from escaping, whereas tumor tissue vasculatures are leaky and hyperpermeable allowing preferential accumulation of nanoparticles in the tumor interstitial space (passive targeting).
crt-41-1-g002.jpg
Fig. 3
Internalization of nanoparticles via receptor-mediated endocytosis. Tumor-specific ligands/antibodies on the nanoparticles bind to cell through an endosome-dependent mechanism. Drug-loaded nanoparticles bypass the drug efflux pump not being recognized when the drug enters cells, leading to high intracellular concentration.
crt-41-1-g003.jpg
Table 1
Examples of non-targeted nanoparticles in clinical development
crt-41-1-i001.jpg
Table 2
Examples of targeted nanoparticles in preclinical and clinical development
crt-41-1-i002.jpg

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Aloe vera gel mediated green synthesis of ruthenium nanoparticles and their potential anticancer activity
      Tanjila Begum, Sangeeta Agarwal, Pranjal Bhuyan, Jumi Das, Akalesh Kumar Verma, Ankur Guha, Mausumi Ganguly
      Next Nanotechnology.2025; 7: 100095.     CrossRef
    • Extracellular vesicles and exosome-like nanovesicles as pioneering oral drug delivery systems
      Jagannath Mondal, Shameer Pillarisetti, Vijayabhaskarreddy Junnuthula, Sachin S. Surwase, Seung Rim Hwang, In-Kyu Park, Yong-kyu Lee
      Frontiers in Bioengineering and Biotechnology.2024;[Epub]     CrossRef
    • Recent Trends in Nanocarrier-Based Drug Delivery System for Prostate Cancer
      Amit Kumar, Akshay Kumar Lunawat, Ashutosh Kumar, Tarun Sharma, Md Moidul Islam, Milan Singh Kahlon, Debanjan Mukherjee, Raj Kumar Narang, Sarjana Raikwar
      AAPS PharmSciTech.2024;[Epub]     CrossRef
    • Advancements in Nutraceutical Delivery: Integrating Nanotechnology and Microencapsulation for Enhanced Efficacy and Bioavailability
      Shanzay Gul, Tahseen Fatima Miano, Anees Mujeeb, Muzafaruddin Chachar, Memoona Islam Majeedano, Ghazal Murtaza, Wazeer Ahmed, Yasha Abid Khanzada, Mariam Ansari
      Matrix Science Pharma.2024; 8(1): 1.     CrossRef
    • Capparis zeylanica-mediated Ag/ZnO nanoparticles and their antiproliferative efficacy via nuclear apoptosis
      P. Suresh, A. Doss, G. Rajeswari, T. P. Kumari Pushpa Rani, R. P. Praveen Pole, S. Satheesh
      Advances in Traditional Medicine.2024; 24(3): 935.     CrossRef
    • Research progress of copper-based metal–organic frameworks for cancer diagnosis and therapy
      Xian Li, Zhifang Ma, Haozheng Wang, Qiang Shi, Zhigang Xie, Jinhai Yu
      Coordination Chemistry Reviews.2024; 514: 215943.     CrossRef
    • Advances in inorganic nanoparticles-based drug delivery in targeted breast cancer theranostics
      Vahid Rahimkhoei, Asaad H. Alzaidy, May Jaleel Abed, Somaye Rashki, Masoud Salavati-Niasari
      Advances in Colloid and Interface Science.2024; 329: 103204.     CrossRef
    • Nanohybrid cerasomes: Advancements in targeted drug and gene delivery
      Kalyani Pathak, Mohammad Zaki Ahmad, Riya Saikia, Partha Protim Borthakur, Pallab Pramanik, Md Ariful Islam, Aparoop Das, Basel A. Abdel-Wahab, Dibyajyoti Das, Saptasikha Gogoi
      European Journal of Medicinal Chemistry Reports.2024; 12: 100178.     CrossRef
    • Bridging the nano-Frontier: revolutionizing lung cancer diagnosis and therapy with nanoparticles
      Joysa Ruby Joseph, Pavithra S, K. Selvakumar, Venkatesh DP
      International Journal of Polymeric Materials and Polymeric Biomaterials.2024; : 1.     CrossRef
    • Receptor-Targeted Nanomedicine for Cancer Therapy
      Arvee Prajapati, Shagun Rangra, Rashmi Patil, Nimeet Desai, Vaskuri G. S. Sainaga Jyothi, Sagar Salave, Prakash Amate, Derajram Benival, Nagavendra Kommineni
      Receptors.2024; 3(3): 323.     CrossRef
    • BODIPY‐based iridium and ruthenium complexes: Synthesis, photophysical, and photochemical properties
      Beyza Cabir, Seda Cetindere
      Journal of the Chinese Chemical Society.2024; 71(11): 1402.     CrossRef
    • Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
      Uttpal Anand, Abhijit Dey, Arvind K. Singh Chandel, Rupa Sanyal, Amarnath Mishra, Devendra Kumar Pandey, Valentina De Falco, Arun Upadhyay, Ramesh Kandimalla, Anupama Chaudhary, Jaspreet Kaur Dhanjal, Saikat Dewanjee, Jayalakshmi Vallamkondu, José M. Pére
      Genes & Diseases.2023; 10(4): 1367.     CrossRef
    • Ursolic acid: a pentacyclic triterpenoid that exhibits anticancer therapeutic potential by modulating multiple oncogenic targets
      Sardul Singh Sandhu, Sharareh Khorami Rouz, Suneel Kumar, Nitin Swamy, Loknath Deshmukh, Arif Hussain, Shafiul Haque, Hardeep Singh Tuli
      Biotechnology and Genetic Engineering Reviews.2023; 39(2): 729.     CrossRef
    • Novel thiosemicarbazone and thiazolidin‐4‐one derivatives containing vanillin core: Synthesis, characterization, and anticancer activity studies
      Feyzi Sinan Tokalı, Halil Şenol, Tuğba Gençoğlu Katmerlikaya, Aydan Dağ, Kıvılcım Şendil
      Journal of Heterocyclic Chemistry.2023; 60(4): 645.     CrossRef
    • The Effects of Curcumin on Inflammasome: Latest Update
      Tarek Benameur, Socorro Vanesca Frota Gaban, Giulia Giacomucci, Francesca Martina Filannino, Teresa Trotta, Rita Polito, Giovanni Messina, Chiara Porro, Maria Antonietta Panaro
      Molecules.2023; 28(2): 742.     CrossRef
    • Approved Nanomedicine against Diseases
      Yuanchao Jia, Yuxin Jiang, Yonglong He, Wanting Zhang, Jiahui Zou, Kosheli Thapa Magar, Hamza Boucetta, Chao Teng, Wei He
      Pharmaceutics.2023; 15(3): 774.     CrossRef
    • Preparation, Characterization and Evaluation of a Novel Drug Carrier for the Controlled Release of Curcumin
      Faseela Kasim, Archana Somasekharan Nair, Aswathy Lalitha Balachandran, Moorikoval Parambil Sooraj, Anoop Somasekharan Nair
      Drug Research.2023; 73(04): 224.     CrossRef
    • Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer
      Jinku Zhang, Jirui Sun, Chong Li, Haizhi Qiao, Zahid Hussain
      Journal of Nanobiotechnology.2023;[Epub]     CrossRef
    • Advanced Delivery System of Polyphenols for Effective Cancer Prevention and Therapy
      Koung Hee Kim, Mi-Ran Ki, Ki Ha Min, Seung Pil Pack
      Antioxidants.2023; 12(5): 1048.     CrossRef
    • Fabrication and characterization of bee venom-loaded nanoliposomes: Enhanced anticancer activity against different human cancer cell lines via the modulation of apoptosis-related genes
      Alaa Abd El-Gawad, Mohamed A. Kenawy, Tamer M. El-Messery, Marwa E. Hassan, Aziza A. El-Nekeety, Mosaad A. Abdel-Wahhab
      Journal of Drug Delivery Science and Technology.2023; 84: 104545.     CrossRef
    • Development and Statistical Optimization of Polymer-Based Nanoparticulate Delivery System for Enhancing Cytarabine Efficacy in Leukemia Treatment
      Nasrullah Jan, Asadullah Madni, Hassan Shah, Safiullah Khan, Qazi Amir Ijaz, Syed Faisal Badshah, Ahsan Ali, Umair Khurshid, Mohammad F. Bostanudin
      Journal of Pharmaceutical Innovation.2023; 18(4): 1713.     CrossRef
    • Hybrid Nanoplatforms Comprising Organic Nanocompartments Encapsulating Inorganic Nanoparticles for Enhanced Drug Delivery and Bioimaging Applications
      Fatih Yanar, Dario Carugo, Xunli Zhang
      Molecules.2023; 28(15): 5694.     CrossRef
    • Current status of Fe-based MOFs in biomedical applications
      Hanping Yang, Donghui Liao, Zhidong Cai, Yuelin Zhang, Alireza Nezamzadeh-Ejhieh, Mingbin Zheng, Jianqiang Liu, Zhi Bai, Hailiang Song
      RSC Medicinal Chemistry.2023; 14(12): 2473.     CrossRef
    • Molecular Mechanism of Inhibition of Glioma by Targeting Autophagy Microtubule-Associated Protein 1A/1B-Light Chain 3 Family via miR-16 with Novel Liposome Nanoparticles
      Chunyang Xing, Weiping Cai, Yiru Fang, Qikun Wang, Yan Huang, Yuzhe Wang, Weiwei Wang
      Journal of Biomedical Nanotechnology.2023; 19(11): 1891.     CrossRef
    • A Comprehensive Review on Targeted Cancer Therapy: New Face of Treatment Approach
      Dipanjan Karati, Dileep Kumar
      Current Pharmaceutical Design.2023; 29(41): 3282.     CrossRef
    • Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy
      Indra Rautela, Aditi Sharma, Pallavi Dheer, Priya Thapliyal, Shweta Sahni, Vimlendu Bhushan Sinha, Manish Dev Sharma
      Drug Delivery and Translational Research.2022; 12(5): 1002.     CrossRef
    • Development and Characterization of 5-Fluorouracil Solid Lipid Nanoparticles for Treatment of Colorectal Cancer
      Poournima Patil, Suresh Killedar, Harinath More, Ganesh Vambhurkar
      Journal of Pharmaceutical Innovation.2022; 17(4): 1268.     CrossRef
    • Synthesis of oleanolic acid hydrazide-hydrazone hybrid derivatives and investigation of their cytotoxic effects on A549 human lung cancer cells
      Şenol Halil, Mercümek Berre, Şahin Rabia Büşra, Kapucu Halil Burak, Hacıosmanoğlu Ebru
      Results in Chemistry.2022; 4: 100317.     CrossRef
    • Therapeutic Nanoparticles: Advantages and Toxicity
      Dr. Lata Ramrakhiani
      Indian Journal of Environment Engineering.2022; 2(1): 19.     CrossRef
    • Green-synthesized gold nanoparticles from black tea extract enhance the chemosensitivity of doxorubicin in HCT116 cells via a ROS-dependent pathway
      Tanushree Das, Snehasis Mishra, Sayoni Nag, Krishna Das Saha
      RSC Advances.2022; 12(15): 8996.     CrossRef
    • Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials
      Natalia Krasteva, Milena Georgieva
      Pharmaceutics.2022; 14(6): 1213.     CrossRef
    • Polymer-Based Materials and their Applications in Image-Guided Cancer Therapy
      Yang Sun, Haitao Ran, Fan Liu
      Current Medicinal Chemistry.2022; 29(8): 1352.     CrossRef
    • Polymeric nanoparticles-siRNA as an emerging nano-polyplexes against ovarian cancer
      Urushi Rehman, Neha Parveen, Afsana Sheikh, Mohammed A.S. Abourehab, Amirhossein Sahebkar, Prashant Kesharwani
      Colloids and Surfaces B: Biointerfaces.2022; 218: 112766.     CrossRef
    • Wnt/β-catenin targeting in liver carcinoma through nanotechnology-based drug repurposing: A review
      Priyadarshini Mohapatra, Natarajan Chandrasekaran
      Biomedicine & Pharmacotherapy.2022; 155: 113713.     CrossRef
    • Immunocyte‐Derived Nanodrugs for Cancer Therapy
      Xiao‐Yu Zhu, Tian‐Yu Wang, Hao‐Ran Jia, Fu‐Gen Wu
      Advanced Functional Materials.2022;[Epub]     CrossRef
    • Nanocarriers and their Types for Targeted Drug Delivery
      Nazma. Shaik, Prasanth. Y
      International Journal of Pharmaceutical Sciences Review and Research.2022; : 21.     CrossRef
    • Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
      Zehra Edis, Junli Wang, Muhammad Khurram Waqas, Muhammad Ijaz, Munazza Ijaz
      International Journal of Nanomedicine.2021; Volume 16: 1313.     CrossRef
    • Novel Green Biosynthesis of 5-Fluorouracil Chromium Nanoparticles Using Harpullia pendula Extract for Treatment of Colorectal Cancer
      Mohammed S. Saddik, Mahmoud M. A. Elsayed, Mohamed Salaheldin A. Abdelkader, Mohamed A. El-Mokhtar, Jelan A. Abdel-Aleem, Ahmed M. Abu-Dief, Mostafa F. Al-Hakkani, Hatem S. Farghaly, Heba A. Abou-Taleb
      Pharmaceutics.2021; 13(2): 226.     CrossRef
    • Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics
      Ajita Jindal, Sounik Sarkar, Aftab Alam
      Frontiers in Chemistry.2021;[Epub]     CrossRef
    • Fabrication of Versatile Hollow Metal–Organic Framework Nanoplatforms for Folate-Targeted and Combined Cancer Imaging and Therapy
      Xiaoli Zeng, Bin Chen, Yibo Song, Xiaofeng Lin, Shu-Feng Zhou, Guowu Zhan
      ACS Applied Bio Materials.2021; 4(8): 6417.     CrossRef
    • Urokinase Plasminogen Activator Receptor-Mediated Targeting of a Stable Nanocomplex Coupled with Specific Peptides for Imaging of Cancer
      Deepshikha Shahdeo, Akshay B. Chandra, Sonu Gandhi
      Analytical Chemistry.2021; 93(34): 11868.     CrossRef
    • Carbon Dots: An Innovative Tool for Drug Delivery in Brain Tumors
      Giovanna Calabrese, Giovanna De Luca, Giuseppe Nocito, Maria Giovanna Rizzo, Sofia Paola Lombardo, Giulia Chisari, Stefano Forte, Emanuele Luigi Sciuto, Sabrina Conoci
      International Journal of Molecular Sciences.2021; 22(21): 11783.     CrossRef
    • Basics to advances in nanotherapy of colorectal cancer
      Ankita Tiwari, Shivani Saraf, Ankit Jain, Pritish K. Panda, Amit Verma, Sanjay K. Jain
      Drug Delivery and Translational Research.2020; 10(2): 319.     CrossRef
    • Molecular Insights into the Loading and Dynamics of Doxorubicin on PEGylated Graphene Oxide Nanocarriers
      Mina Mahdavi, Ali Fattahi, Emad Tajkhorshid, Sasan Nouranian
      ACS Applied Bio Materials.2020; 3(3): 1354.     CrossRef
    • Preparation and characterization of stable fluorescent As4S4/ZnS/Fe3O4 nanosuspension capped by Poloxamer 407 and folic acid
      Z. Lukáčová Bujňáková, O. Shpotyuk, I. Syvorotka, P. Demchenko, E. Dutková, E. Tóthová, Z. Bártová
      Applied Nanoscience.2020; 10(12): 4651.     CrossRef
    • “Watson–Crick GC”-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy
      Meijin Chen, Shiduan Chen, Fukai Zhu, Fanfan Wang, Haina Tian, Zhongxiong Fan, Sunkui Ke, Zhenqing Hou, Yang Li
      Journal of Materials Chemistry B.2020; 8(17): 3829.     CrossRef
    • The Emerging Role of Curcumin in the Modulation of TLR-4 Signaling Pathway: Focus on Neuroprotective and Anti-Rheumatic Properties
      Maria Antonietta Panaro, Addolorata Corrado, Tarek Benameur, Cantatore Francesco Paolo, Daniela Cici, Chiara Porro
      International Journal of Molecular Sciences.2020; 21(7): 2299.     CrossRef
    • CRGDK-Functionalized PAMAM-Based Drug-Delivery System with High Permeability
      Dongfang Liu, Chao Wang, Jian Yang, Yanli An, Rui Yang, Gaojun Teng
      ACS Omega.2020; 5(16): 9316.     CrossRef
    • Nanomaterials as potential transporters of HDAC inhibitors
      Cristabelle De Souza, Zhao Ma, Aaron Raymond Lindstrom, Biswa Prasun Chatterji
      Medicine in Drug Discovery.2020; 6: 100040.     CrossRef
    • Natural ligand-receptor mediated loading of siRNA in milk derived exosomes
      Shruti Shandilya, Payal Rani, Suneel Kumar Onteru, Dheer Singh
      Journal of Biotechnology.2020; 318: 1.     CrossRef
    • Inhibition of Glioma Cells’ Proliferation by Doxorubicin-Loaded Exosomes via Microfluidics


      Abhimanyu Thakur, Rakesh Kumar Sidu, Heng Zou, Md Kowsar Alam, Mengsu Yang, Youngjin Lee
      International Journal of Nanomedicine.2020; Volume 15: 8331.     CrossRef
    • Synthesis, In Silico Prediction and In Vitro Evaluation of Antitumor Activities of Novel Pyrido[2,3-d]pyrimidine, Xanthine and Lumazine Derivatives
      Samar El-Kalyoubi, Fatimah Agili
      Molecules.2020; 25(21): 5205.     CrossRef
    • Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics
      Fabiana de Sousa Cunha, Laise Nayra dos Santos Pereira, Thâmara Pryscilla de Costa e Silva, Roberto Alves de Sousa Luz, Anderson Nogueira Mendes
      Journal of Drug Targeting.2019; 27(7): 732.     CrossRef
    • Nanocarriers for drug delivery applications
      Munusamy Chamundeeswari, John Jeslin, Madan Lal Verma
      Environmental Chemistry Letters.2019; 17(2): 849.     CrossRef
    • Folic-Acid-Adorned PEGylated Graphene Oxide Interferes with the Cell Migration of Triple Negative Breast Cancer Cell Line, MDAMB-231 by Targeting miR-21/PTEN Axis through NFκB
      Arijita Basu, Priyanka Upadhyay, Avijit Ghosh, Dipankar Chattopadhyay, Arghya Adhikary
      ACS Biomaterials Science & Engineering.2019; 5(1): 373.     CrossRef
    • Innovative nano-carriers in anticancer drug delivery-a comprehensive review
      Peng Dong, K.P. Rakesh, H.M. Manukumar, Yasser Hussein Eissa Mohammed, C.S. Karthik, S. Sumathi, P. Mallu, Hua-Li Qin
      Bioorganic Chemistry.2019; 85: 325.     CrossRef
    • Liposomal Taro Lectin Nanocapsules Control Human Glioblastoma and Mammary Adenocarcinoma Cell Proliferation
      Anna C. N. T. F. Corrêa, Mauricio A. Vericimo, Andriy Dashevskiy, Patricia R. Pereira, Vania M. F. Paschoalin
      Molecules.2019; 24(3): 471.     CrossRef
    • Modulation of Biological Activities in Glioblastoma Mediated by Curcumin
      Teresa Trotta, Maria A. Panaro, Elona Prifti, Chiara Porro
      Nutrition and Cancer.2019; 71(8): 1241.     CrossRef
    • Laponite-based Nanomaterials for Biomedical Applications: A Review
      Sabya S. Das, Neelam, Kashif Hussain, Sima Singh, Afzal Hussain, Abdul Faruk, Mike Tebyetekerwa
      Current Pharmaceutical Design.2019; 25(4): 424.     CrossRef
    • Efficient nanocarriers of siRNA therapeutics for cancer treatment
      Md Abdus Subhan, V.P. Torchilin
      Translational Research.2019; 214: 62.     CrossRef
    • Hydrophobically modified inulin-based micelles: Transport mechanisms and drug delivery applications for breast cancer
      Siddharth S. Kesharwani, Rakesh Dachineni, G. Jayarama Bhat, Hemachand Tummala
      Journal of Drug Delivery Science and Technology.2019; 54: 101254.     CrossRef
    • Perspectives of Molecularly Imprinted Polymer-Based Drug Delivery Systems in Cancer Therapy
      Andreea Elena Bodoki, Bogdan-Cezar Iacob, Ede Bodoki
      Polymers.2019; 11(12): 2085.     CrossRef
    • Nanomaterials as nanocarriers: a critical assessment why these are multi-chore vanquisher in breast cancer treatment
      Sania Naz, Hira Shahzad, Attarad Ali, Muhammad Zia
      Artificial Cells, Nanomedicine, and Biotechnology.2018; 46(5): 899.     CrossRef
    • Antimicrobial peptides, nanotechnology, and natural metabolites as novel approaches for cancer treatment
      Michel L. Leite, Nicolau B. da Cunha, Fabricio F. Costa
      Pharmacology & Therapeutics.2018; 183: 160.     CrossRef
    • A novel self-assembled nanoparticle platform based on pectin-eight-arm polyethylene glycol-drug conjugates for co-delivery of anticancer drugs
      Yanxue Liu, Kefeng Liu, Xiaomin Li, Shangzhen Xiao, Dan Zheng, Pengbo Zhu, Chunxiao Li, Jing Liu, Jing He, Jiandu Lei, Luying Wang
      Materials Science and Engineering: C.2018; 86: 28.     CrossRef
    • Synthesis, Optical, and Structural Studies of Iron Sulphide Nanoparticles and Iron Sulphide Hydroxyethyl Cellulose Nanocomposites from Bis-(Dithiocarbamato)Iron(II) Single-Source Precursors
      Athandwe Paca, Peter Ajibade
      Nanomaterials.2018; 8(4): 187.     CrossRef
    • Protein adsorption and macrophage uptake of zwitterionic sulfobetaine containing micelles
      Aijing Lu, Zhengzhong Wu, Xianglin Luo, Suming Li
      Colloids and Surfaces B: Biointerfaces.2018; 167: 252.     CrossRef
    • Self-Assembled Nanoparticles Platform Based on Pectin-Dihydroartemisinin Conjugates for Codelivery of Anticancer Drugs
      Yanxue Liu, Dan Zheng, Yunyun Ma, Juan Dai, Chunxiao Li, Shangzhen Xiao, Kefeng Liu, Jing Liu, Luying Wang, Jiandu Lei, Jing He
      ACS Biomaterials Science & Engineering.2018;[Epub]     CrossRef
    • Evaluation of chromosomal aberrations induced by 188Re-dendrimer nanosystem on B16f1 melanoma cells
      Marcos Tassano, Natalia Oddone, Marcelo Fernández, Williams Porcal, María Fernanda García, Wilner Martínez-López, Juan Claudio Benech, Pablo Cabral
      International Journal of Radiation Biology.2018; 94(7): 664.     CrossRef
    • A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically
      Xin-shuai Wang, Xue-zhen Ding, Xiao-cen Li, Yixuan He, De-jiu Kong, Li Zhang, Xiao-chen Hu, Jun-qiang Yang, Meng-qi Zhao, She-gan Gao, Tzu-yin Lin, Yuanpei Li
      Nanomedicine: Nanotechnology, Biology and Medicine.2018; 14(7): 2103.     CrossRef
    • Electroneutral polymersomes for combined cancer chemotherapy
      Noorjahan Aibani, Heather Nesbitt, Nino Marino, Joanna Jurek, Caolin O'Neill, Chloe Martin, Ivana Di Bari, Yingjie Sheng, Kieran Logan, Susan Hawthorne, Anthony McHale, John F. Callan, Bridgeen Callan
      Acta Biomaterialia.2018; 80: 327.     CrossRef
    • A novel honokiol liposome: formulation, pharmacokinetics, and antitumor studies
      Chuchu Zhou, Chenqi Guo, Wenhao Li, Juan Zhao, Qin Yang, Tiantian Tan, Zhuoya Wan, Jianxia Dong, Xu Song, Tao Gong
      Drug Development and Industrial Pharmacy.2018; 44(12): 2005.     CrossRef
    • Multifunctional nanoparticle developments in cancer diagnosis and treatment
      Sepideh Parvanian, Seyed Mojtaba Mostafavi, Meysam Aghashiri
      Sensing and Bio-Sensing Research.2017; 13: 81.     CrossRef
    • Carbon nanotubes: a novel material for multifaceted applications in human healthcare
      Sandeep Kumar, Ruma Rani, Neeraj Dilbaghi, K. Tankeshwar, Ki-Hyun Kim
      Chemical Society Reviews.2017; 46(1): 158.     CrossRef
    • Targeting nanocarriers containing antisense oligonucleotides to cancer cell
      Parth Patel, Y.K. Agrawal
      Journal of Drug Delivery Science and Technology.2017; 37: 97.     CrossRef
    • Targeted si-RNA with liposomes and exosomes (extracellular vesicles): How to unlock the potential
      Sophia Antimisiaris, Spyridon Mourtas, Konstantina Papadia
      International Journal of Pharmaceutics.2017; 525(2): 293.     CrossRef
    • Down–regulation of cyclin–dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1
      Tanmoy Bhowmik, Antony Gomes
      Chemico-Biological Interactions.2017; 268: 119.     CrossRef
    • Targeted Magnetic Nanotheranostics of Cancer
      Irina Belyanina, Olga Kolovskaya, Sergey Zamay, Ana Gargaun, Tatiana Zamay, Anna Kichkailo
      Molecules.2017; 22(6): 975.     CrossRef
    • Targeted delivery of bromelain using dual mode nanoparticles: synthesis, physicochemical characterization, in vitro and in vivo evaluation
      Rozita Nasiri, Javad Hamzehalipour Almaki, Ani Idris, Mahtab Nasiri, Muhammad Irfan, Fadzilah Adibah Abdul Majid, Hamid Rashidi Nodeh, Rosnani Hasham
      RSC Advances.2017; 7(64): 40074.     CrossRef
    • Self-Assembled Pectin-Conjugated Eight-Arm Polyethylene Glycol–Dihydroartemisinin Nanoparticles for Anticancer Combination Therapy
      Yanxue Liu, Qi Qi, Xiaomin Li, Jing Liu, Luying Wang, Jing He, Jiandu Lei
      ACS Sustainable Chemistry & Engineering.2017; 5(9): 8097.     CrossRef
    • Ursolic acid nanoparticles inhibit cervical cancer growth in vitro and in vivo via apoptosis induction
      Shaoguang Wang, Xiaomei Meng, Yaozhong Dong
      International Journal of Oncology.2017; 50(4): 1330.     CrossRef
    • Preparation, Characterization, and Preliminary In Vitro Testing of Nanoceria-Loaded Liposomes
      Agostina Grillone, Tianshu Li, Matteo Battaglini, Alice Scarpellini, Mirko Prato, Shinji Takeoka, Gianni Ciofani
      Nanomaterials.2017; 7(9): 276.     CrossRef
    • Small Interfering RNA in Milk Exosomes Is Resistant to Digestion and Crosses the Intestinal Barrier In Vitro
      Shruti Shandilya, Payal Rani, Suneel Kumar Onteru, Dheer Singh
      Journal of Agricultural and Food Chemistry.2017; 65(43): 9506.     CrossRef
    • Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin
      Farrukh Aqil, Radha Munagala, Jeyaprakash Jeyabalan, Ashish Kumar Agrawal, Ramesh Gupta
      The AAPS Journal.2017; 19(6): 1691.     CrossRef
    • Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery
      Yu Tong Tam, Kenneth Kin Wah To, Albert Hee Lum Chow
      Colloids and Surfaces B: Biointerfaces.2016; 139: 249.     CrossRef
    • Advances in silica based nanoparticles for targeted cancer therapy
      Yannan Yang, Chengzhong Yu
      Nanomedicine: Nanotechnology, Biology and Medicine.2016; 12(2): 317.     CrossRef
    • Supramolecular assembly of a succinyl-calix[4]arene derivative in multilamellar vesicles
      Giuseppe Granata, Grazia M. L. Consoli, Raffaella Lo Nigro, Graziella Malandrino, Corrada Geraci
      Supramolecular Chemistry.2016; 28(5-6): 377.     CrossRef
    • Etirinotecan pegol for the treatment of breast cancer
      Elena López-Miranda, Javier Cortés
      Expert Opinion on Pharmacotherapy.2016; 17(5): 727.     CrossRef
    • Study of anti-cancer properties of green silver nanoparticles against MCF-7 breast cancer cell lines
      Shweta Rajawat, Rajnish Kurchania, Katherukamen Rajukumar, Shreyas Pitale, Sonali Saha, M.S. Qureshi
      Green Processing and Synthesis.2016;[Epub]     CrossRef
    • Upconversion nanoparticles for tumor imaging with near-infrared radiation
      V. V. Rocheva, D. A. Khochenkov, A. N. Generalova, A. V. Nechaev, V. A. Semchishen, E. V. Stepanova, V. I. Sokolov, E. V. Khaydukov, V. Ya. Panchenko
      Bulletin of the Russian Academy of Sciences: Physics.2016; 80(4): 467.     CrossRef
    • Conjugation of Docetaxel with Multiwalled Carbon Nanotubes and Codelivery with Piperine: Implications on Pharmacokinetic Profile and Anticancer Activity
      Kaisar Raza, Dinesh Kumar, Chanchal Kiran, Manish Kumar, Santosh Kumar Guru, Pramod Kumar, Shweta Arora, Gajanand Sharma, Shashi Bhushan, O. P. Katare
      Molecular Pharmaceutics.2016; 13(7): 2423.     CrossRef
    • Development of hematin conjugated PLGA nanoparticle for selective cancer targeting
      Md. Lutful Amin, Dami Kim, SeJin Kim
      European Journal of Pharmaceutical Sciences.2016; 91: 138.     CrossRef
    • Biosynthesized Vitis vinifera seed gold nanoparticles induce apoptotic cell death in A431 skin cancer cells
      J. Grace Nirmala, S. Akila, M. S. A. Muthukumar Nadar, R. T. Narendhirakannan, Suvro Chatterjee
      RSC Advances.2016; 6(85): 82205.     CrossRef
    • Biodegradable polymeric nanoparticles containing gold nanoparticles and Paclitaxel for cancer imaging and drug delivery using photoacoustic methods
      Yanjie Wang, Eric M. Strohm, Yang Sun, Zhaoxia Wang, Yuanyi Zheng, Zhigang Wang, Michael C. Kolios
      Biomedical Optics Express.2016; 7(10): 4125.     CrossRef
    • Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives
      Amit Alexander, Ajazuddin, Ravish J. Patel, Swarnlata Saraf, Shailendra Saraf
      Journal of Controlled Release.2016; 241: 110.     CrossRef
    • Cancer active targeting by nanoparticles: a comprehensive review of literature
      Remon Bazak, Mohamad Houri, Samar El Achy, Serag Kamel, Tamer Refaat
      Journal of Cancer Research and Clinical Oncology.2015; 141(5): 769.     CrossRef
    • Synthesis, characterization, and pharmacological evaluation of some novel thiadiazoles and thiazoles incorporating pyrazole moiety as anticancer agents
      Sobhi M. Gomha, Taher A. Salah, Abdou O. Abdelhamid
      Monatshefte für Chemie - Chemical Monthly.2015; 146(1): 149.     CrossRef
    • Delivery systems for siRNA drug development in cancer therapy
      Cong-fei Xu, Jun Wang
      Asian Journal of Pharmaceutical Sciences.2015; 10(1): 1.     CrossRef
    • Advances in Combination Therapies Based on Nanoparticles for Efficacious Cancer Treatment: An Analytical Report
      Serge Mignani, Maria Bryszewska, Barbara Klajnert-Maculewicz, Maria Zablocka, Jean-Pierre Majoral
      Biomacromolecules.2015; 16(1): 1.     CrossRef
    • Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
      Edgar Pérez-Herrero, Alberto Fernández-Medarde
      European Journal of Pharmaceutics and Biopharmaceutics.2015; 93: 52.     CrossRef
    • Carbon nanotubes: Properties, biomedical applications, advantages and risks in patients and occupationally-exposed workers
      M Lamberti, P Pedata, N Sannolo, S Porto, A De Rosa, M Caraglia
      International Journal of Immunopathology and Pharmacology.2015; 28(1): 4.     CrossRef
    • Novel biodegradable heparin-coated nanocomposite system for targeted drug delivery
      Amaneh Javid, Shahin Ahmadian, Ali Akbar Saboury, Seyed Mehdi Kalantar, Saeed Rezaei-Zarchi
      RSC Adv..2014; 4(26): 13719.     CrossRef
    • Intracellular transport of nanodiamond particles in human endothelial and epithelial cells
      Katarzyna Solarska-Ściuk, Agnieszka Gajewska, Sława Glińska, Maciej Studzian, Sylwia Michlewska, Łucja Balcerzak, Janusz Skolimowski, Bogumiła Kolago, Grzegorz Bartosz
      Chemico-Biological Interactions.2014; 219: 90.     CrossRef
    • Preclinical development of siRNA therapeutics: Towards the match between fundamental science and engineered systems
      M. Videira, A. Arranja, D. Rafael, R. Gaspar
      Nanomedicine: Nanotechnology, Biology and Medicine.2014; 10(4): 689.     CrossRef
    • Effect of functionalized and non-functionalized nanodiamond on the morphology and activities of antioxidant enzymes of lung epithelial cells (A549)
      Katarzyna Solarska-Ściuk, Agnieszka Gajewska, Sława Glińska, Sylwia Michlewska, Łucja Balcerzak, Agnieszka Jamrozik, Janusz Skolimowski, Květoslava Burda, Grzegorz Bartosz
      Chemico-Biological Interactions.2014; 222: 135.     CrossRef
    • Preparation of 5-fluorouracil-loaded Nanoparticles and Study of Interaction with Gastric Cancer Cells
      Yu-Ling Fan, Bing-Yu Fan, Qiang Li, Hai-Xiao Di, Xiang-Yu Meng, Na Ling
      Asian Pacific Journal of Cancer Prevention.2014; 15(18): 7611.     CrossRef
    • Passive targeting of nanoparticles to cancer: A comprehensive review of the literature
      REMON BAZAK, MOHAMAD HOURI, SAMAR EL ACHY, WAEL HUSSEIN, TAMER REFAAT
      Molecular and Clinical Oncology.2014; 2(6): 904.     CrossRef
    • Antileukemic potential of PEGylated gold nanoparticle conjugated with protein toxin (NKCT1) isolated from Indian cobra (Naja kaouthia) venom
      Tanmoy Bhowmik, Partha Pratim Saha, Anjan Dasgupta, Antony Gomes
      Cancer Nanotechnology.2013; 4(1-3): 39.     CrossRef
    • pH-sensitive Liposomes for Drug Delivery in Cancer Treatment
      Diego dos Santos Ferreira, Sávia Caldeira de Araújo Lopes, Marina Santiago Franco, Mônica Cristina Oliveira
      Therapeutic Delivery.2013; 4(9): 1099.     CrossRef
    • The inclusion complex of 4-hydroxynonenal with a polymeric derivative of β-cyclodextrin enhances the antitumoral efficacy of the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model
      Stefania Pizzimenti, Eric Ciamporcero, Piergiorgio Pettazzoni, Simona Osella-Abate, Mauro Novelli, Cristina Toaldo, Miriam Husse, Martina Daga, Rosalba Minelli, Agnese Bisazza, Paolo Ferruti, Elisabetta Ranucci, Maria Grazia Bernengo, Chiara Dianzani, Fio
      Free Radical Biology and Medicine.2013; 65: 765.     CrossRef
    • Highly efficient double-stranded RNA transfection of penaeid shrimp using cationic liposomes
      Nuttapon Apiratikul, Boon-ek Yingyongnarongkul, Wanchai Assavalapsakul
      Aquaculture Research.2013; 45(1): 106.     CrossRef
    • Preparation, Physicochemical Characterization, and Cell Viability Evaluation of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid
      Sávia Caldeira de Araújo Lopes, Marcus Vinícius Melo Novais, Cláudia Salviano Teixeira, Kinulpe Honorato-Sampaio, Márcio Tadeu Pereira, Lucas Antônio Miranda Ferreira, Fernão Castro Braga, Mônica Cristina Oliveira
      BioMed Research International.2013; 2013: 1.     CrossRef
    • Carbon nanotubes as a novel drug delivery system for anticancer therapy: a review
      Swatantra Kumar Singh Kushwaha, Saurav Ghoshal, Awani Kumar Rai, Satyawan Singh
      Brazilian Journal of Pharmaceutical Sciences.2013; 49(4): 629.     CrossRef
    • A Novel 5-Fluorouracil-Loaded Polyelectrolyte Nanoparticle Formulation
      Yu Ling Fan, Bing Yu Fan, Qiang Li, Shuang Leng, Li Hua Ma
      Advanced Materials Research.2013; 690-693: 518.     CrossRef
    • Poly(ethylene carbonate) Nanoparticles as Carrier System for Chemotherapy Showing Prolonged in vivo Circulation and Anti‐Tumor Efficacy
      Thomas Renette, Damiano Librizzi, Thomas Endres, Olivia Merkel, Moritz Beck‐Broichsitter, Nadja Bege, Holger Petersen, Catherine Curdy, Thomas Kissel
      Macromolecular Bioscience.2012; 12(7): 970.     CrossRef
    • Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
      Susana Patricia Egusquiaguirre, Manuela Igartua, Rosa María Hernández, José Luis Pedraz
      Clinical and Translational Oncology.2012; 14(2): 83.     CrossRef
    • The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells
      Prachi Joshi, Soumyananda Chakraborti, Jaime E. Ramirez-Vick, Z.A. Ansari, Virendra Shanker, Pinak Chakrabarti, Surinder P. Singh
      Colloids and Surfaces B: Biointerfaces.2012; 95: 195.     CrossRef
    • Submicron-size biodegradable polymer-based didanosine particles for treating HIV at early stage: anin vitrostudy
      Gurudutta Pattnaik, Biswadip Sinha, Biswajit Mukherjee, Saikat Ghosh, Sandip Basak, Subhasish Mondal, Tanmoy Bera
      Journal of Microencapsulation.2012; 29(7): 666.     CrossRef
    • Polypeptide-based vesicles: formation, properties and application for drug delivery
      Bin Tian, Xiaoguang Tao, Tianyang Ren, Yan Weng, Xia Lin, Yu Zhang, Xing Tang
      Journal of Materials Chemistry.2012; 22(34): 17404.     CrossRef
    • Modeling and Improvement of Breast Cancer Site Temperature Profile by Implantation of Onion-Like Quantum-Dot Quantum-Well Heteronanocrystal in Tumor Site
      A. SalmanOgli, A. Rostami
      IEEE Transactions on Nanotechnology.2012; 11(6): 1183.     CrossRef
    • Aptamer-labeled PLGA nanoparticles for targeting cancer cells
      Athulya Aravind, Saino Hanna Varghese, Srivani Veeranarayanan, Anila Mathew, Yutaka Nagaoka, Seiki Iwai, Takahiro Fukuda, Takashi Hasumura, Yasuhiko Yoshida, Toru Maekawa, D. Sakthi Kumar
      Cancer Nanotechnology.2012; 3(1-6): 1.     CrossRef
    • Sustained targeting of Bcr–Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy
      Sarbari Acharya, Sanjeeb K. Sahoo
      Biomaterials.2011; 32(24): 5643.     CrossRef
    • Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms
      Alicia Fernandez-Fernandez, Romila Manchanda, Anthony J. McGoron
      Applied Biochemistry and Biotechnology.2011; 165(7-8): 1628.     CrossRef
    • Liposome based delivery systems in pancreatic cancer treatment: From bench to bedside
      Feng Yang, Chen Jin, Yongjian Jiang, Ji Li, Yang Di, Quanxing Ni, Deliang Fu
      Cancer Treatment Reviews.2011; 37(8): 633.     CrossRef
    • PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
      Sarbari Acharya, Sanjeeb K. Sahoo
      Advanced Drug Delivery Reviews.2011; 63(3): 170.     CrossRef
    • Nanomaterials: Applications in Cancer Imaging and Therapy
      José A. Barreto, William O’Malley, Manja Kubeil, Bim Graham, Holger Stephan, Leone Spiccia
      Advanced Materials.2011;[Epub]     CrossRef
    • Informatics and standards for nanomedicine technology
      Dennis G. Thomas, Fred Klaessig, Stacey L. Harper, Martin Fritts, Mark D. Hoover, Sharon Gaheen, Todd H. Stokes, Rebecca Reznik‐Zellen, Elaine T. Freund, Juli D. Klemm, David S. Paik, Nathan A. Baker
      WIREs Nanomedicine and Nanobiotechnology.2011; 3(5): 511.     CrossRef
    • Targeted photodynamic therapy — a promising strategy of tumor treatment
      Andrzej M. Bugaj
      Photochemical & Photobiological Sciences.2011; 10(7): 1097.     CrossRef
    • Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice
      Ahmed M. Al-Abd, Ki-Yun Hong, Soo-Chang Song, Hyo-Jeong Kuh
      Journal of Controlled Release.2010; 142(1): 101.     CrossRef
    • Fullerene–Porphyrin Nanostructures in Photodynamic Therapy
      Carolina Constantin, Monica Neagu, Rodica-Mariana Ion, Mihaela Gherghiceanu, Crina Stavaru
      Nanomedicine.2010; 5(2): 307.     CrossRef
    • The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
      Ngoc Trinh Huynh, Emilie Roger, Nolwenn Lautram, Jean-Pierre Benoît, Catherine Passirani
      Nanomedicine.2010; 5(9): 1415.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Advances of Cancer Therapy by Nanotechnology
      Cancer Res Treat. 2009;41(1):1-11.   Published online March 31, 2009
      Close
    • XML DownloadXML Download
    Advances of Cancer Therapy by Nanotechnology
    Image Image Image
    Fig. 1 Illustration of (A) polymer based nanoparticles; (B). Liposome based nanoparticles; and (C). Iron oxide or gold nanoparticles.
    Fig. 2 Schematic diagram of nanoparticle accumulation in tumor tissue through EPR effect. Normal tissue vasculatures are lined by tight endothelial cells, thereby preventing nanoparticle drugs from escaping, whereas tumor tissue vasculatures are leaky and hyperpermeable allowing preferential accumulation of nanoparticles in the tumor interstitial space (passive targeting).
    Fig. 3 Internalization of nanoparticles via receptor-mediated endocytosis. Tumor-specific ligands/antibodies on the nanoparticles bind to cell through an endosome-dependent mechanism. Drug-loaded nanoparticles bypass the drug efflux pump not being recognized when the drug enters cells, leading to high intracellular concentration.
    Advances of Cancer Therapy by Nanotechnology

    Examples of non-targeted nanoparticles in clinical development

    Examples of targeted nanoparticles in preclinical and clinical development

    Table 1 Examples of non-targeted nanoparticles in clinical development

    Table 2 Examples of targeted nanoparticles in preclinical and clinical development


    Cancer Res Treat : Cancer Research and Treatment
    Close layer
    TOP